help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2006-1355
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Habibi, J.
Right arrow Articles by Sowers, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Habibi, J.
Right arrow Articles by Sowers, J. R.
Endocrinology Vol. 148, No. 5 2181-2188
Copyright © 2007 by The Endocrine Society

Rosuvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Decreases Cardiac Oxidative Stress and Remodeling in Ren2 Transgenic Rats

Javad Habibi, Adam Whaley-Connell, Mahnaz A. Qazi, Melvin R. Hayden, Shawna A. Cooper, Anthony Tramontano, John Thyfault, Craig Stump, Carlos Ferrario, Ranganath Muniyappa and James R. Sowers

University of Missouri School of Medicine (J.H., A.W.-C., M.R.H., J.T., J.R.S.), Diabetes and Cardiovascular Laboratory (J.H., A.W.-C., M.Q., M.R.H., J.T., J.R.S.), and Harry S. Truman Veterans Affairs Medical Center (J.H., A.W.-C., J.T., J.R.S.), Columbia, Missouri 65212; Wake Forest University School of Medicine (C.F.), Winston-Salem, North Carolina 27157; State University of New York, Stony Brook, School of Medicine at Winthrop-University Hospital (A.T.), Stony Brook, New York 11794; The New York Harbor Veterans Affairs Healthcare System (R.M.), Brooklyn Campus, Brooklyn, New York 11209; and University of Arizona and Arizona Veterans Affairs Medical Center (S.A.C., C.S.), Tucson, Arizona 85724-5218

Address all correspondence and requests for reprints to: James R. Sowers, M.D., F.A.C.E., F.A.C.P., F.A.H.A., Professor of Medicine and Physiology, Department of Internal Medicine, Division of Endocrinology, D109 HSC Diabetes Center, Columbia, Missouri 65212. E-mail: sowersj{at}deptofmed.arizona.edu.

Angiotensin-II (Ang-II)-stimulated increases in nicotinamide adenine dinucleotide phosphate reduced (NADPH) oxidase activity and oxidative stress are known to play a key role in cardiac remodeling. Inhibition of isoprenylation and activation of small G proteins, such as Rac1, a component of NADPH oxidase, may mediate the antioxidant actions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins). In this study, we investigated the effects of rosuvastatin on cardiac oxidative stress and remodeling in transgenic rats (Ren2) overexpressing the mouse renin gene with elevated cardiac levels of Ang-II. We treated 6- to 7-wk-old Ren2 rats and age-matched Sprague-Dawley (SD) rats with rosuvastatin (10 mg/kg·d) or vehicle for 3 wk. At the end of the treatment period, left ventricular mass, wall thickness, ejection fraction (by echocardiography), and cardiac remodeling (by light microscopy and immunohistochemistry) were assessed. In addition, myocardial content of nitrotyrosine, malondialdehyde, NADPH-oxidase subunits (gp91phox, p40phox, and p22phox), and Rac1 were analyzed by immunochemistry. Systolic blood pressure was significantly higher in Ren2 rats, compared with SD rats (P < 0.05); rosuvastatin had no significant effect on systolic blood pressure in either group. In Ren2, but not SD rats, rosuvastatin significantly improved the ventricular ejection fraction, cardiac hypertrophy, and perivascular fibrosis (P < 0.05). In addition, rosuvastatin administration significantly decreased the accentuated myocardial gp91phox, p40phox, p22phox, and Rac1 expression. These changes were accompanied by a parallel reduction in myocardial lipid peroxidation (nitrotyrosine and malondialdehyde content) (P < 0.05). These results suggest that in vivo statin treatment through its direct actions on the heart reduces oxidative stress and remodeling including ventricular mass regression in the Ang-II-dependent Ren2 model.




This article has been cited by other articles:


Home page
HypertensionHome page
A. M. Briones, N. Rodriguez-Criado, R. Hernanz, A. B. Garcia-Redondo, R. R. Rodrigues-Diez, M. J. Alonso, J. Egido, M. Ruiz-Ortega, and M. Salaices
Atorvastatin Prevents Angiotensin II-Induced Vascular Remodeling and Oxidative Stress
Hypertension, July 1, 2009; 54(1): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
C. M. Ferrario, J. Varagic, J. Habibi, S. Nagata, J. Kato, M. C. Chappell, A. J. Trask, K. Kitamura, A. Whaley-Connell, and J. R. Sowers
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy
Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H1184 - H1192.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Habibi, A. Whaley-Connell, M. R. Hayden, V. G. DeMarco, R. Schneider, S. D. Sowers, P. Karuparthi, C. M. Ferrario, and J. R. Sowers
Renin Inhibition Attenuates Insulin Resistance, Oxidative Stress, and Pancreatic Remodeling in the Transgenic Ren2 Rat
Endocrinology, November 1, 2008; 149(11): 5643 - 5653.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Whaley-Connell, J. Habibi, S. A. Cooper, V. G. DeMarco, M. R. Hayden, C. S. Stump, D. Link, C. M. Ferrario, and J. R. Sowers
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat
Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E103 - E109.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Whaley-Connell, J. Habibi, R. Nistala, S. A. Cooper, P. R. Karuparthi, M. R. Hayden, N. Rehmer, V. G. DeMarco, B. T. Andresen, Y. Wei, et al.
Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin Treatment
Hypertension, February 1, 2008; 51(2): 474 - 480.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. Yagi, K.-i. Aihara, Y. Ikeda, Y. Sumitomo, S. Yoshida, T. Ise, T. Iwase, K. Ishikawa, H. Azuma, M. Akaike, et al.
Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II Induced Cardiovascular Remodeling and Renal Insufficiency
Circ. Res., January 4, 2008; 102(1): 68 - 76.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G.-X. Zhang, X.-M. Lu, S. Kimura, and A. Nishiyama
Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation
Cardiovasc Res, November 1, 2007; 76(2): 204 - 212.
[Abstract] [Full Text] [PDF]


Home page
Ther Adv Cardiovasc DisHome page
L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers
Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence
Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Cooper, A. Whaley-Connell, J. Habibi, Y. Wei, G. Lastra, C. Manrique, S. Stas, and J. R. Sowers
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2009 - H2023.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E. M. Redout, M. J. Wagner, M. J. Zuidwijk, C. Boer, R. J.P. Musters, C. van Hardeveld, W. J. Paulus, and W. S. Simonides
Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species
Cardiovasc Res, September 1, 2007; 75(4): 770 - 781.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Whaley-Connell, G. Govindarajan, J. Habibi, M. R. Hayden, S. A. Cooper, Y. Wei, L. Ma, M. Qazi, D. Link, P. R. Karuparthi, et al.
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat
Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E355 - E363.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society